Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 15/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.41 |
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
| ▸ | ADH7 | P40394 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4090626 | 0.80 | LOX (0.54) | LOXLOXL2L3MBTL1 | |
| SCHEMBL4096471 | 0.74 | ADH1B (0.41) | ADH1BADH1CADH1AADH7L3MBTL1 | |
| SCHEMBL18643569 | 0.74 | LOX (0.59) | LOXLOXL2L3MBTL1KMT2A | |
| SCHEMBL6209587 | 0.72 | LOX (0.58) | LOXLOXL2KCNH2AOC3LOXL3 | |
| SCHEMBL1838092 | 0.72 | LOX (0.58) | LOXLOXL2KCNH2AOC3LOXL3 | |
| SCHEMBL3131218 | 0.72 | LOX (0.86) | LOXLOXL2KCNH2AOC3LOXL3 | |
| SCHEMBL4086191 | 0.71 | FFAR1 (0.42) | ADH1BADH1CADH1AADH7MEN1 | |
| Hydrochloric Acid SCHEMBL15486681 | 0.71 | LOX (0.83) | LOXLOXL2KCNH2AOC3LOXL3 | |
| SCHEMBL19436416 | 0.70 | LOX (0.57) | LOXLOXL2L3MBTL1KMT2A | |
| SCHEMBL13425238 | 0.69 | LOX (0.54) | LOXLOXL2KCNH2AOC3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| EP-1861384-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Sterix Limited (GB) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006100502-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | STERIX LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | LOX 3915/4885LOXL2 4213/4885ADH1B 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.